We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KR:NYSEKroger Company (The) Analysis

Data as of 2026-03-10 - not real-time

$73.37

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Kroger delivered Q4 earnings of $1.28 per share, beating the Zacks consensus of $1.20 and expanding margins, which helped push the stock to $73.37, comfortably above its 20‑day (≈69.3) and 50‑day (≈65.4) simple moving averages. The technical picture is bullish, with the MACD line (≈1.71) sitting above its signal (≈1.34) and a positive histogram, while the RSI at 65 signals near‑term strength but also hints at overbought conditions. Analyst sentiment remains positive, with a consensus “buy” rating and a median price target of $73, closely matching the current price.
Despite the short‑term momentum, the stock appears **overvalued**: the DCF fair value of roughly $43 is far below the market price, and the trailing P/E of 47.6 dwarfs the forward P/E of 13.0. The dividend yield of 1.9% is supported by an 87% payout ratio, raising questions about long‑term sustainability given thin profit margins (≈0.7%) and a very high debt‑to‑equity ratio (>400%). The company’s strong free cash flow and ongoing share repurchase program provide some cushion, but the combination of high valuation, leverage, and modest growth suggests caution for longer horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Q4 earnings beat and margin expansion
  • Bullish MACD and price above key moving averages
  • Stable trading volume supporting liquidity

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Forward earnings growth (trailing EPS $1.54 → forward EPS $5.65)
  • Attractive dividend yield but high payout ratio
  • Share repurchase program reducing share count

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant overvaluation relative to DCF fair value
  • Very high debt‑to‑equity ratio and thin profit margins
  • Uncertainty around dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth1.20%
Profit Margin0.69%
P/E Ratio47.6
ROE14.41%
ROA5.64%
Debt/Equity415.77
P/B Ratio5.9
Op. Cash Flow$7.3B
Free Cash Flow$3.4B

Technical Analysis

TrendNeutral
RSI65.1
Support$66.04
Resistance$74.85
MA 20$69.32
MA 50$65.41
MA 200$67.19
MACDBullish
VolumeStable
Fear & Greed Index77.64

Valuation

Fair Value$43.21
Target Price$74.38
Upside/Downside1.38%
GradeOvervalued
TypeGrowth
Dividend Yield1.91%

Risk Assessment

Beta-0.28
Volatility34.58%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.